Products
Pre-made Licaminlimab benchmark antibody ( scFv, anti-TNFA/TNF therapeutic antibody, Anti-DIF/TNFSF2/TNLG1F Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-310
Pre-Made Licaminlimab biosimilar, scFv, Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
| Catalog No. | Package | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| GMP-Bios-ab-310-1mg | 1mg | 3090 | ||
| GMP-Bios-ab-310-10mg | 10mg | Inquiry | ||
| GMP-Bios-ab-310-100mg | 100mg | Inquiry | ||
| GMP-Bios-ab-310-xmg | ≥100mg | Inquiry | ||
| Shipping Cost: | 760.00 | |||
| Total: | ||||
Description
| Products Name (INN Index) | Pre-Made Licaminlimab biosimilar, scFv, Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody |
| INN Name | Licaminlimab |
| Target | TNF |
| Format | scFv |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | na |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | na |
| Companies | Oculis |
| Conditions Approved | na |
| Conditions Active | Dry eye syndrome |
| Conditions Discontinued | na |
| Development Tech | na |
<